Pfizer Attacks 'False' Biosimilar Info, Urges FDA Action

Law360 (August 28, 2018, 6:12 PM EDT) -- Major biotech companies have smeared biosimilars in "false and misleading" ways that have undermined the copycat products and perhaps flouted federal law, Pfizer Inc. charged in a petition released Monday calling for U.S. Food and Drug Administration action.

Pfizer's citizen petition, which was posted online late Monday, contained blunt attacks on the promotional efforts of Amgen Inc., Genentech Inc. and Johnson & Johnson. The petition flatly accused all three companies of making deceptive statements about biosimilars, which are lower-cost versions of expensive biologics.

After noting that biosimilar sales have been sluggish, Pfizer asserted that "a major factor contributing to this slow...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!